ATR

AptarGroup, Inc. 10-Q Summary: Quarter Ended June 30, 2002

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2002, for AptarGroup, Inc., a Delaware corporation. The company operates in the packaging components industry, developing, manufacturing, and selling consumer product dispensing systems. Operations are organized into two reportable segments: Dispensing Systems (non-aerosol pumps, closures, valves) and SeaquistPerfect (aerosol valves and accessories). The company has significant international operations, with approximately 52% of sales generated in Europe.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue: Net sales increased 1% year-over-year for the quarter ($233.2M vs. $231.8M) but decreased 3% for the six-month period ($451.9M vs. $464.7M). Core sales (excluding currency effects) declined 1% for the quarter and 2% for the six months.
• Profitability: Operating income increased 13% for the quarter ($29.0M vs. $25.6M) but decreased 10% for the six months ($51.2M vs. $56.9M). The year-over-year decline in six-month operating income is largely attributed to non-recurring charges in the prior year (Strategic Initiative and patent settlement) and goodwill amortization which ceased in 2002.
• Cost of Sales: Increased as a percentage of net sales to 63.7% in Q2 2002 from 62.0% in Q2 2001. Drivers included rising material prices (LIFO impact), unfavorable currency translation on European costs, and underutilized fixed costs due to lower fragrance/cosmetic sales.
• Segment Performance:
  • Dispensing Systems: Revenue and EBIT declined due to weakness in the fragrance/cosmetic market and price pressure.
  • SeaquistPerfect: Revenue increased 12.4% and EBIT increased 80.7% for the quarter, driven by strong sales of aerosol valves in the household market and cost savings.
• One-Time Items: The prior year included a $4.2 million patent dispute settlement and significant Strategic Initiative charges ($7.3M in Q2 2001). Current year Strategic Initiative charges were minimal ($0.9M in Q2 2002) as the project nears completion.

Guidance, Outlook, and Risks

• Outlook: Management anticipates sales to the fragrance/cosmetic market will remain below prior-year levels in Q3 2002, though expected to improve from Q1/Q2 2002. Sales to personal care, household, food/beverage, and pharmaceutical markets are expected to increase year-over-year in Q3.
• Earnings Guidance: Diluted earnings per share for the third quarter (ending Sept 30, 2002) are projected in the range of $0.47 to $0.52.
• Liquidity: The company maintains a $100 million revolving credit facility with $27 million available. Capital expenditures for 2002 are estimated at $80 million.
• Risks: Key risks include foreign currency exchange fluctuations (primary exposure to the Euro), raw material costs, competition, and the failure to achieve anticipated cost savings from restructuring initiatives.

Investor Verification Checklist

• Core Sales Trend: Verify the continued weakness in the fragrance/cosmetic market and the timeline for recovery.
• Cost Structure: Monitor the impact of rising raw material costs and LIFO reserves on gross margins.
• Strategic Initiative Completion: Confirm that the $11.1 million total cost for the Strategic Initiative has been fully incurred and that expected efficiency gains are materializing.
• Currency Exposure: Assess the impact of Euro strength on future earnings translation and cost of sales.
• Capital Allocation: Review the balance between capital expenditures ($80M estimated for 2002) and free cash flow generation.